SCHEMBL21580673

SCHEMBL21580673

Cc1ccc(Oc2cc(I)ccn2)cc1OC(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 5/20 0.35
▸ HAO1 Q9UJM8 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ KDR P35968 6/20 0.34
▸ BRAF P15056 2/20 0.34
▸ HRH4 Q9H3N8 1/20 0.32
▸ RAF1 P04049 1/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ AXL P30530 1/20 0.32
▸ SCN10A Q9Y5Y9 1/20 0.31
▸ MAPK14 Q16539 1/20 0.30
▸ ABL1 P00519 1/20 0.30
▸ BCR P11274 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21581601 0.86 DRD1 (0.40) DRD1HAO1NPC1CASP3RAB9A
SCHEMBL21580706 0.83 PDGFRB (0.40) DRD1HAO1
SCHEMBL21580663 0.80 HAO1 (0.51) DRD1HAO1NPC1RAB9A
SCHEMBL21580680 0.79 HAO1 (0.38) DRD1HAO1NPC1CASP3RAB9A
SCHEMBL21580697 0.76 MRGPRX4 (0.40) NPC1CASP3RAB9ASENP8SENP7
SCHEMBL17354613 0.76 KDM4E (0.41) HAO1NPC1RAB9ASCN10A
SCHEMBL21581646 0.75 PDGFRA (0.40) DRD1KDRAXL
SCHEMBL23005292 0.75 CYP1A2 (0.32) —
SCHEMBL20309036 0.75 NOTUM (0.37) EPHX2
SCHEMBL30488651 0.75 CYP1A2 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof BIONOMICS LIMITED (AU) 2024-09-17 — — US disclosed
EP-3853216-B1 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS BIONOMICS LTD (AU) 2024-09-11 — — EP disclosed
EP-3853216-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF Bionomics Limited (AU) 2021-07-28 — — EP disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 — — WO disclosed
WO-2019222816-A1 SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12090146-B2 Substituted-pyridinyl compounds and uses thereof GABRE, GAP43, GRIN2A DRD1 449/4885HAO1 4264/4885NPC1 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback